Carl Wayne White
Physician at Milwaukee St, Denver, CO
License number
Colorado 24593
Issued Date
Jun 10, 1982
Renew Date
May 1, 2015
Expiration Date
Apr 30, 2017
Type
Physician
Address
Address
641 Milwaukee St, Denver, CO 80206
Professional information
See more information about Carl Wayne White at trustoria.com
Dr. Carl W White - MD (Doctor of Medicine)
Dr. Carl W White - MD (Doctor of Medicine)
Hospitals:
13123 E 16Th Ave, Aurora 80045
National Jewish Health
1400 Jackson St, Denver 80206
13123 E 16Th Ave, Aurora 80045
National Jewish Health
1400 Jackson St, Denver 80206
National Jewish Health
1400 Jackson St, Denver 80206
13123 E 16Th Ave, Aurora 80045
National Jewish Health
1400 Jackson St, Denver 80206
Education:
Medical Schools
Baylor College Of Medicine
Graduated: 1978
Baylor College Of Medicine
Graduated: 1978
Carl White, Denver CO
Carl White, Denver CO
Work:
National Jewish Health
1400 Jackson St, Denver, CO 80206 Childrens Hospital Pulm. Dept
13123 E 16Th Ave, Aurora, CO 80045 National Jewish Health Glenwood Clinic
1450 E Valley Rd, Basalt, CO 81621 National Jewish Health Glenwood Clinic
820 Castle Valley Blvd, New Castle, CO 81647
1400 Jackson St, Denver, CO 80206 Childrens Hospital Pulm. Dept
13123 E 16Th Ave, Aurora, CO 80045 National Jewish Health Glenwood Clinic
1450 E Valley Rd, Basalt, CO 81621 National Jewish Health Glenwood Clinic
820 Castle Valley Blvd, New Castle, CO 81647
Marker For Cancer Prognosis And Methods Related Thereto
Marker For Cancer Prognosis And Methods Related Thereto
US Patent:
2011025, Oct 13, 2011
Filed:
Apr 15, 2011
Appl. No.:
13/087607
Inventors:
Aftab Ahmad - Aurora CO, US
Carl W. White - Denver CO, US
Carl W. White - Denver CO, US
Assignee:
NATIONAL JEWISH HEALTH - Denver CO
International Classification:
C12Q 1/02, C12Q 1/68
US Classification:
435 611, 435 29, 435 614, 435 61
Abstract:
The present invention is related to the novel discovery that HIF-2α, but not HIF-1α, selectively regulates adenosine Areceptor in endothelial cells, thereby revealing a unique and hitherto unknown pathway by which HIF-2αcan regulate angiogenesis independent of HIF-1α. This discovery allows for design of new diagnostic tools and novel therapies targeted against angiogenesis-associated diseases, such as cancer. In another aspect, the present invention shows that Areceptor expression is a marker of the developing lung, and can be used as a marker of lung diseases, such as pulmonary hypertension.
Marker For Cancer Prognosis And Methods Related Thereto
Marker For Cancer Prognosis And Methods Related Thereto
US Patent:
2013015, Jun 20, 2013
Filed:
Oct 29, 2012
Appl. No.:
13/662898
Inventors:
NATIONAL JEWISH HEALTH - Denver CO, US
Carl W. White - Denver CO, US
Carl W. White - Denver CO, US
Assignee:
NATIONAL JEWISH HEALTH - Denver CO
International Classification:
C12Q 1/68, G01N 33/68
US Classification:
435 611, 435 71
Abstract:
The present invention is related to the novel discovery that HIF-2α, but not HIF-1 a, selectively regulates adenosine Areceptor in endothelial cells, thereby revealing a unique and hitherto unknown pathway by which HIF-2α can regulate angiogenesis independent of HIF-1α. This discovery allows for design of new diagnostic tools and novel therapies targeted against angiogenesis-associated diseases, such as cancer. In another aspect, the present invention shows that Areceptor expression is a marker of the developing lung, and can be used as a marker of lung diseases, such as pulmonary hypertension.
Methods For Treatment And Diagnosis Of Pulmonary Diseases Based On The Expression Of Serca2 Protein
Methods For Treatment And Diagnosis Of Pulmonary Diseases Based On The Expression Of Serca2 Protein
US Patent:
2010008, Apr 8, 2010
Filed:
Oct 5, 2009
Appl. No.:
12/573605
Inventors:
Shama Ahmad - Aurora CO, US
Carl W. White - Denver CO, US
Carl W. White - Denver CO, US
International Classification:
A61K 38/16, A61K 31/7052, A61K 31/56, A61K 31/135, A61K 31/44, G01N 33/68, G01N 33/48, A61P 11/00
US Classification:
514 12, 514 44 R, 514169, 514653, 514342, 436 86, 436 94
Abstract:
The present invention is directed to methods of treatment of cystic fibrosis. The invention includes a method for treatment of cystic fibrosis in a patient by increasing the activity of sarcoendoplasmic reticulum calcium ATPase (SERCA) in a patient. More specifically, the step of increasing SERCA activity can include but is not limited to, administration of SERCA protein or its homologues, gene therapy to restore or enhance SERCA activity, or the administration of compounds stimulating the activity of endogenous SERCA. Reference herein to SERCA, can include in preferred embodiments, the isoform SERCA2, which is the principal lung isoform of SERCA. The present invention is based on the finding that SERCA2 (a calcium pump) is deficient (not 100%) in the lung epithelial cells of cystic fibrosis samples.
Product And Process For Liquefaction Of Mucus Or Sputum
Product And Process For Liquefaction Of Mucus Or Sputum
US Patent:
7534438, May 19, 2009
Filed:
Mar 2, 2007
Appl. No.:
11/681587
Inventors:
Carl W. White - Denver CO, US
Assignee:
National Jewish Health - Denver CO
International Classification:
A61K 45/00, A61K 38/00, C07K 14/00
US Classification:
4241851, 424450, 514 2, 514 17, 514 18, 514824, 514826, 514886, 530329, 530330, 530399
Abstract:
Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system.
Methods For Treating Injury Associated With Exposure To An Alkylating Species
Methods For Treating Injury Associated With Exposure To An Alkylating Species
US Patent:
2011013, Jun 9, 2011
Filed:
May 26, 2009
Appl. No.:
12/993469
Inventors:
Brian J. Day - Denver CO, US
Carl W. White - Denver CO, US
Carl W. White - Denver CO, US
Assignee:
National Jewish Health - Denver CO
International Classification:
A61K 31/555, A61P 43/00
US Classification:
514185
Abstract:
Compounds may be administered to prevent or rescue organ injury following exposure to alkylating agents, such as sulfur mustards. The compounds may be substituted metalloporphyrins.
Product And Process For Liquefaction Of Mucus Or Sputum
Product And Process For Liquefaction Of Mucus Or Sputum
US Patent:
7195766, Mar 27, 2007
Filed:
Sep 10, 2003
Appl. No.:
10/660118
Inventors:
Carl W. White - Denver CO, US
Assignee:
National Jewish Medical and Research Center - Denver CO
International Classification:
A61K 45/05, A61K 38/00, C07K 13/00
US Classification:
4241851, 424 852, 424450, 514 2, 514 17, 514 18, 514826, 514886, 530329, 530330, 530399
Abstract:
Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system.
Product And Process For Liquefaction Of Mucus Or Sputum
Product And Process For Liquefaction Of Mucus Or Sputum
US Patent:
2013020, Aug 15, 2013
Filed:
Oct 3, 2012
Appl. No.:
13/644099
Inventors:
National Jewish Health - , US
Carl W. WHITE - Denver CO, US
Carl W. WHITE - Denver CO, US
Assignee:
NATIONAL JEWISH HEALTH - Denver CO
International Classification:
A61K 38/44
US Classification:
424 944
Abstract:
Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system.
Mucolytic And Anti-Elastase Compounds And Methods Of Use Thereof
Mucolytic And Anti-Elastase Compounds And Methods Of Use Thereof
US Patent:
2005026, Nov 24, 2005
Filed:
Mar 24, 2005
Appl. No.:
11/090916
Inventors:
Carl White - Denver CO, US
Greg Del Val - Saint-Aubin/NE, CH
Rees Lee - Centennial CO, US
Greg Del Val - Saint-Aubin/NE, CH
Rees Lee - Centennial CO, US
Assignee:
National Jewish Medical and Research Center - Denver CO
The United States Government as Represented by the Secretary of the Navy - Silver Spring MD
The United States Government as Represented by the Secretary of the Navy - Silver Spring MD
International Classification:
A61K038/06, A61K031/385, A61L009/04, A61K009/14
US Classification:
424046000, 514018000, 514440000
Abstract:
Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. Also disclosed are compositions and methods for inhibiting elastase in a patient. The compositions contains a compound containing a dithiol active-site in reduced state and optionally further contains a reducing system.